Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells

Advances in Enzyme Regulation

Volumn 50, Issue 1, 2010, Pages 285-307

  McCubrey, James A ^a   Abrams, Stephen L ^a   Stadelman, Kristin ^a   Chappell, William H ^a   LaHair, Michelle ^a   Ferland, Richard A ^a   Steelman, Linda S ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ANIMAL; BREAST TUMOR; CANCER STEM CELL; DRUG EFFECT; DRUG RESISTANCE; ENZYME ACTIVATION; FEMALE; GENETICS; HUMAN; METABOLISM; METASTASIS; PATHOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CELL LINE, TUMOR; DRUG RESISTANCE; ENZYME ACTIVATION; FEMALE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION;

EID: 77953573564     PISSN: 00652571     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.advenzreg.2009.10.016     Document Type: Article

References (170)

1. Adachi T., Kar S., Wang M., Carr B.I. Transient and sustained ERK phosphorylation and nuclear translocation in growth control. J Cell Physiol 2002, 192:151-159.
2. Alessi D.R., James S.R., Downes C.P., Holmes A.B., Gaffney P.R., Reese C.B., et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 1997, 7:261-269.
3. Allan L.A., Morrice N., Brady S., Magee G., Pathak S., Clarke P.R. Inhibition of caspase-9 by phosphorylation at Thr125 by ERK MAPK. Nat Cell Biol 2003, 5:647-654.
4. Andrieux L.O., Fautrei A., Bessard A., Guillouzo A., Baffet G., Langouët S. GATA-1 is essential in EGF-meditated induction of nucleotide excision repair activity and ERCCI expression through ERK2 in human hepatoma cells. Cancer Res 2007, 67:2114-2123.
5. Aplin A.E., Stewart S.A., Assoian R.K., Juliano R.L. Integrin-mediated adhesion regulates ERK nuclear translocation and phosphorylation of Elk-1. J Cell Biol 2001, 153:273-282.
6. Avruch J. MAP kinase pathways: the first twenty years. Biochem Biophys Acta 2007, 1773:1150-1161.
7. Bacher U., Haferlach T., Schoch C., Kern W., Schnittger S. Implications of NRAS mutations in AML: a study of 2502 patients. Blood 2006, 107:3847-3853.
8. Balan V., Leicht D.T., Zhu J., Balan K., Kaplun A., Singh-Gupta V., et al. Identification of novel in vivo Raf-1 phosphorylation sites mediating positive feedback Raf-1 regulation by extracellular signal-regulated kinase. Mol Biol Cell 2006, 17:141-153.
9. Beghini A., Peterlongo P., Ripamonti C.B., Larizza L., Cairoli R., Morra E., et al. c-Kit mutations in core binding factor leukemias. Blood 2000, 95:726-727.
10. Bellacosa A., Testa J.R., Staal S.P., Tsichlis P.N. A retroviral oncogene, Akt, encoding a serine-threonine kinase containing an SH2-like region. Science 1991, 254:274-277.
11. Blalock W.L., Navolanic P.M., Steelman L.S., Shelton J.G., Moye P.W., Lee J.T., et al. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia. Leukemia 2003, 17:1058-1067.
12. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
13. Bortul R., Tazzari P.L., Cappellini A., Tabellini G., Billi A.M., Bareggi R., et al. Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-κB activation and cFLIP(L) up-regulation. Leukemia 2003, 17:379-389.
14. Brummer T., Naegele H., Reth M., Misawa Y. Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf. Oncogene 2003, 22:8823-8834.
15. Cardone M.H., Roy N., Stennicke H.R., Salvesen G.S., Franke T.F., Stanbridge E., et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998, 282:1318-1321.
16. Carter B.Z., Milella M., Tsao T., McQueen T., Schober W.D., Hu W., et al. Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia 2003, 17:2081-2089.
17. Catalanotti F., Reyes G., Jesenberger V., Galabova-Kovacs G., de Matos Simoes R., Carugo O., et al. A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal. Nat Struct Mol Biol 2009, 16:294-303.
18. Cheng G.Z., Zhang W., Wang L.H. Regulation of cancer cell survival, migration, and invasion by Twist: AKT2 comes to interplay. Cancer Res 2008, 68:957-960.
19. Ciuffreda L, McCubrey JA, Milella M. Cytoplasmic signaling intermediates PI3K/PTEN/Akt/mTOR and Raf/MEK/ERK pathways as therapeutic targets for anti-cancer and anti-angiogenesis treatments. Curr Signal Transduct Ther, in press.
20. Coffer P.J., Woodgett J.R. Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur J Biochem 1991, 201:475-481.
21. Come C., Magnino F., Bibeau F., DeSanta B.P., Becker K.F., Theillet C., et al. Snail and slug play distinct roles during breast carcinoma progression. Clin Cancer Res 2006, 12:5395-5402.
22. Criswell T.L., Arteaga C.L. Modulation of NF-κB activity and E-cadherin by the type III transforming growth factor beta receptor regulates cell growth and motility. J Biol Chem 2007, 282:32491-32500.
23. Da Silva I.D., Dias-Netto E., Villanova F.E., Yamamoto L., Baracat E.C., Lima G.R., et al. Tamoxifen down-regulates CaMKII messenger RNA levels in normal human breast tissue. Clin Exp Obstet Gynecol 2004, 31:204-208.
24. Dahl C., Guidberg P. The genome and epigenome of malignant melanoma. APMIS 2007, 115:1161-1176.
25. Datta K., Franke T.F., Chan T.O., Makris A., Yang S.I., Kaplan D.R., et al. AH/PH domain-mediated interaction between Akt molecules and its potential role in Akt regulation. Mol Cell Biol 1995, 15:2304-2310.
26. Davis R.J. Transcriptional regulation by MAP kinases. Mol Reprod Dev 1995, 42:459-467.
27. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
28. Davis J.M., Navolanic P.M., Weinstein-Oppenheimer C.R., Steelman L.S., Hu W., Konopleva M., et al. Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin Cancer Res 2003, 9:1161-1170.
29. de Grouw E.P., Raaijmakers M.H., Boezeman J.B., van der Reijden B.A., van de Locht L.T., de Witte T.J., et al. Preferential expression of a high number of ATP binding cassette transporters in both normal and leukemic CD34+CD38- cells. Leukemia 2006, 20:750-754.
30. de Jonge-Peeters S.D., Kuipers F., de Vries E.G., Vellenga E. ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit Rev Oncol Hematol 2007, 62:214-226.
31. Deng T., Karin M. c-Fos transcriptional activity stimulated by H-Ras-activated protein kinase distinct from JNK and ERK. Nature 1994, 371:171-175.
32. Deng X., Kornblau S.M., Ruvolo P.P., May W.S. Regulation of Bcl2 phosphorylation and potential significance for leukemic cell chemoresistance. J Natl Cancer Inst Monogr 2001, 28:30-37.
33. Dérijard B., Raingeaud J., Barrett T., Wu I.H., Han J., Ulevitch R.J., et al. Independent human MAP kinase signal transduction pathways defined by MEK and MKK isoforms. Science 1995, 267:682-685.
34. Detry C., Lamour V., Castronovo V., Bellahcene A. CREB-1 and AP-1 transcription factors JunD and Fra-2 regulate bone sialoprotein gene expression in human breast cancer cells. Bone 2008, 42:422-431.
35. Di Cristofano A., Pandolfi P.P. The multiple roles of PTEN in tumor suppression. Cell 2000, 100:387-390.
36. Doepfner K.T., Spertini O., Arcaro A. Autocrine insulin-like growth factor-1 signaline promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway. Leukemia 2007, 21:1921-1930.
37. Dougherty M.K., Muller J., Ritt D.A., Zhou M., Zhou X.Z., Copeland T.D., et al. Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell 2005, 17:215-224.
38. Easton J.B., Houghton P.J. mTOR and cancer therapy. Oncogene 2006, 25:6436-6446.
39. Eblen S.T., Catling A.D., Assanah M.C., Weber M.J. Biochemical and biological functions of the N-terminal, noncatalytic domain of extracellular signal-regulated kinase 2. Mol Cell Biol 2001, 21:249-259.
40. Faridi J., Wang L., Endemann G., Roth R.A. Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo. Clin Cancer Res 2003, 9:2933-2939.
41. Filigheddu N., Cutrupi S., Porporato P.E., Riboni F., Baldanzi G., Chianale F., et al. Diacylglycerol kinase is required for HGF-induced invasiveness and anchorage-independent growth of MDA-MB-231 breast cancer cells. Anticancer Res 2007, 27:1489-1492.
42. Fingar D.C., Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004, 23:3151-3171.
43. Fisher G.A., Sikic B.I. Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am 1995, 9:363-382.
44. Flotho S., Valcamonica S., Mach-Pascual S., Schmahl G., Corral L., Ritterbach J., et al. RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia 1999, 13:32-37.
45. Franke T.F., Yang S.I., Chan T.O., Datta K., Kazlauskas A., Morrison D.K., et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 1995, 81:727-736.
46. Franke T.F., Kaplan D.R., Cantley L.C., Toker A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 1997, 275:665-668.
47. Franklin R.A., Atherfold P.A., McCubrey J.A. Calcium-induced ERK activation in human T lymphocytes occurs via p56(Lck) and CaM-kinase. Mol Immunol 2000, 37:675-683.
48. Fransén K., Klintenäs M., Osterström A., Dimberg J., Monstein H.J., Söderkvist P. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 2004, 25:527-533.
49. Gal H., Amariglio N., Trakhtenbrot L., Jacob-Hirsh J., Margalit O., Avigdor A., et al. Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. Leukemia 2006, 20:2147-2154.
50. Garcia R., Franklin R.A., McCubrey J.A. EGF induces cell motility and multi-drug resistance gene expression in breast cancer cells. Cell Cycle 2006, 5:2820-2826.
51. Gardner H.P., Ha S.I., Reynolds C., Chodosh L.A. The CaM kinase, PNCK, is spatially and temporally regulated during murine mammary gland development and may identify an epithelial cell subtype involved in breast cancer. Cancer Res 2000, 60:5571-5577.
52. Garnett M.J., Marais R. Guilty as charged: B-Raf is a human oncogene. Cancer Cell 2004, 6:313-319.
53. Gavert N., Ben-Ze'ev A. Epithelial-mesenchymal transition and the invasive potential of tumors. Trends Mol Med 2008, 9:9.
54. Ghosh S., Tergaonkar V., Rothlin C.V., Correa R.G., Bottero V., Bist P., et al. Essential role of tuberous sclerosis genes TSC1 and TSC2 in NF-κB activation and cell survival. Cancer Cell 2006, 10:215-226.
55. Giesler S., Borresen-Dale A.L., Johnsen H., Aas T., Giesler J., Akslen L.A., et al. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Caner Res 2003, 9:5582-5588.
56. Goel V.K., Lazar A.J., Warneke C.L., Redston M.S., Haluska F.G. Examination of mutations in B-Raf, N-Ras and PTEN in primary cutataneous melanoma. J Inv Dermatol 2005, 126:154-160.
57. Greenberg P.L., Lee S.J., Advani R., Tallman M.S., Sikic B.I., Letendre L., et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 2004, 22:1078-1086.
58. Hollestelle A., Elstrodt F., Nagel J.H.A., Kallemeijn W.W., Schutte M. Phosphatidylinositol-3-OH kinase or Ras pathway mutati9ons in human breast cancer cell lines. Mol Cancer Res 2007, 5:195-201.
59. House S.J., Singer H.A. CaMKII-delta isoform regulation of neointima formation after vascular injury. Arterioscler Thromb Vasc Biol 2008, 28:441-447.
60. Howe C.J., LaHair M.M., Maxwell J.A., Lee J.T., Robinson P.J., Rodriguez-Mora O., et al. Participation of the calcium/calmodulin-dependent kinases in hydrogen peroxide-induced Ikappa B phosphorylation in human T lymphocytes. J Biol Chem 2002, 277:30469-30476.
61. Howe C.J., Lahair M.M., McCubrey J.A., Franklin R.A. Redox regulation of the calcium/calmodulin-dependent protein kinases. J Biol Chem 2004, 279:44573-44581.
62. Inder K., Harding A., Plowman S.J., Philips M.R., Parton R.G., Hancock J.F. Activation of the MAPK module from different spatial locations generates distinct system outputs. Mol Biol Cell 2008, 19:4776-4784.
63. Inoki K., Zhu T., Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 15:577-590.
64. Janz M., Stühmer T., Vassilev L.T., Bargou R.C. Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells. Leukemia 2007, 21:772-779.
65. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics. CA Cancer J Clin 2005, 55:10-30.
66. Jia W., Yu C., Rahmani M., Krystal G., Sausville E.A., Dent P., et al. Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways. Blood 2003, 102:1824-1832.
67. Jiang B.H., Liu L.Z. AKT signaling in regulating angiogenesis. Curr Cancer Drug Targets 2008, 8:19-26.
68. Kang-Park S., Lee Y.I. PTEN modulates insulin-like growth factor II (IGF-II)-mediated signaling; the protein phosphatase activity of PTEN downregulates IGF-II expression in hepatoma cells. FEBS Lett 2003, 545:203-208.
69. Kim J.B., Lee K.M., Ko E., Han W., Lee J.E., Shin I., et al. Berberine inhibits growth of the breast cancer cell lines MCF-7 and MDA-MB-231. Planta Med 2008, 74:39-42.
70. Kim J.B., Ko E., Han W., Sahin I., Park S.Y., Noh D.Y. Berberine diminishes the side population and ABCG2 transporter expression in MCF-7 breast cancer cells. Planta Med 2008, 74:1693-1700.
71. Kiyoi H., Naoe T., Nakano Y., Yokota S., Minami S., Miyawaki S., et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999, 93:3074-3080.
72. Kojima K., Konopleva M., McQueen T., O'Brien S., Plunkett W., Andreeff M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanism and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 2006, 108:993-1000.
73. Kojima K., Konopleva M., Samudio I.J., Schober W.D., Bornmann W.G., Andreeff M. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML. Cell Cycle 2006, 5:2778-2786.
74. Kojima K., Konopleva M., Samudio I.J., Ruvolo V., Andreeff M. Mitogen-activated protein kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells. Cancer Res 2007, 67:3210-3219.
75. Kozma S.C., Bogaard M.E., Buser K., Saurer S.M., Bos J.L., Groner B., et al. The human c-Kirsten ras gene is activated by a novel mutation in condon 13 in the breast carcinoma cell line MDA-MB231. Nucleic Acids Res 1987, 15:5963-5971.
76. Krause D.S., Van Etten R.A. Right on target: eradicating leukemic stem cells. Trends Mol Med 2007, 13:470-481.
77. Kwiatkowski D.J. Tuberous sclerosis: from tubers to mTOR. Ann Hum Genet 2003, 67:87-96.
78. Lahair M.M., Howe C.J., Rodriguez-Mora O., McCubrey J.A., Franklin R.A. Molecular pathways leading to oxidative stress-induced phosphorylation of Akt. Antioxid Redox Signal 2006, 8:1749-1756.
79. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
80. Lee J.T., Lehmann B.D., Terrrian D.M., Chappell W.H., Stivala F., Libra M., et al. Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle 2008, 7:1745-1762.
81. Lehman B.D., McCubrey J.A., Jefferson H.S., Paine M.S., Chappell W.H., Terrian D.M. A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells. Cell Cycle 2007, 6:595-605.
82. Leicht D.T., Balan V., Kaplun A., Singh-Gupta V., Kaplun L., Dobson M., et al. Raf kinases: function, regulation and role in human cancer. Biochem Biophys Acta 2007, 1773:1196-1213.
83. Li W., Zhu T., Guan K.L. Transformation potential of Ras isoforms correlates with activation of phosphatidylinositol 3-kinase but not ERK. J Biol Chem 2004, 279:37398-37406.
84. Libra M., Malaponte G., Navolanic P.M., Gangemi P., Bevelacqua V., Proietti L., et al. Analysis of BRAF mutation in primary and metastatic melanoma. Cell Cycle 2006, 4:968-970.
85. Ligresti G., Militello L., Steelman L.S., Cavallaro A., Basile F., Nicoletti F., et al. PIK3CA mutations in human solid tumors. Cell Cycle 2009, 8:1352-1358.
86. Liu L., Cash T.P., Jones R.G., Keith B., Thompson C.B., Simon M.C. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol Cell 2006, 21:521-531.
87. Liu J., He C., Zhou K., Wang J., Kang J.X. Coptis extracts enhance the anticancer effect of estrogen receptor antagonists on human breast cancer cells. BBRC 2009, 78:174-178.
88. Longo P.G., Laurenti L., Gobessi S., Petlickovski A., Pelosi M., Chiusolo P., et al. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia 2007, 21:110-120.
89. Mahimainathan L., Choudhury G.G. Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase. J Biol Chem 2004, 279:15258-15268.
90. Mangiolini M., Statti G., Vivacqua A., Gabriele S., Rago V., Loisso M., et al. J Steroid Biochem Mol Biol 2001, 82:315-322.
91. Marais R., Light Y., Paterson H.F., Marshall C.J. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J 1995, 14:3136-3145.
92. Marais R., Light Y., Paterson H.F., Mason C.S., Marshall C.J. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem 1997, 272:4378-4383.
93. Martelli A.M., Nyakern M., Tabellini G., Bortul R., Tazzari P.L., Evangelisti C., et al. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 2006, 20:911-928.
94. Martelli A.M., Tazzari P.L., Evangelisti C., Chiarini F., Blalock W.L., Billi A.M., et al. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. Curr Med Chem 2007, 14:2009-2023.
95. Martelli A.M., Evangelisti C., Chiarini F., Grimaldi C., Manzoli L., McCubrey J.A. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opin Investig Drugs 2009, 18:1333-1349.
96. Mason C.S., Springer C.J., Cooper R.G., Superti-Furga G., Marshall C.J., Marais R. Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J 1999, 18:2137-2148.
97. McCubrey J.A., May W.S., Duronio V., Mufson A. Serine/threonine phosphorylation in cytokine signal transduction. Leukemia 2000, 14:9-21.
98. McCubrey J.A., Steelman L.S., Abrams S.L., Lee J.T., Chang F., Bertrand F.E., et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006, 46:249-279.
99. McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Wong E.W., Chang F., et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007, 1773:1263-1284.
100. McCubrey J.A., Abrams S.L., Ligresti G., Misaghian N., Wong E.T., Basecke J., et al. Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. Leukemia 2008, 22:2080-2090.
101. McCubrey J.A., Steelman L.S., Abrams S.L., Bertrand F.E., Ludwig D.E., Basecke J., et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008, 22:708-722.
102. Melnikova V.O., Mourad-Zeidan A.A., Lev D.C., Bar-Eli M. Platelet-activating factor mediates MMP-2 expression and activation via phosphorylation of cAMP-response element-binding protein and contributes to melanoma metastasis. J Biol Chem 2006, 281:2911-2922.
103. Mercure M.Z., Ginnan R.P.D., Singer H.A. CaM Kinase II-{delta}2 dependent regulation of vascular smooth muscle cell polarization and migration. Am J Physiol Cell Physiol 2008, 2:2.
104. Morel A.-P., Lievre M., Thomas C., Hinkal G., Ansieau S., Puisieuz A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008, 3:2888.
105. Nakao M., Yokota S., Iwai T., Kaneko H., Horiike S., Kashima K., et al. Internal tandem duplication of the FLT3 gene found in acute myeloid leukemia. Leukemia 1996, 10:1911-1918.
106. Neubauer A., Dodge R.K., George S.L., Davey F.R., Silver R.T., Schiffer C.A., et al. Prognostic importance of mutations in the Ras proto-oncogenes in de novo acute myeloid leukemia. Blood 1994, 83:1603-1611.
107. 2+/calmodulin-dependent protein kinase (CaM-kinase) IV by CaM-kinase kinase in Jurkat T lymphocytes. J Biol Chem 1995, 270:30464-30469.
108. Pederson-Bjergaard J., Christiansen D.H., Desta F., Andersen M.K. Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2006, 20:1943-1949.
109. Planas-Silva M.D., Waltz P.K. Estrogen promotes reversible epithelial-to-mesenchymal-like transition and collective motility in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 2007, 104:11-21.
110. Plas D.R., Thomas G. Tubers and tumors: rapamycin therapy for benign and malignant tumors. Curr Opin Cell Biol 2009, 21:230-236.
111. Pluta A., Nyman U., Joseph B., Robak T., Zhivotovsky B., Smolewski P. The role of p73 in hematological malignancies. Leukemia 2006, 20:757-766.
112. Ponti C., Gibellini D., Boin F., Melloni E., Manzoli F.A., Cocco L., et al. Role of CREB transcription factor in c-fos activation in natural killer cells. Eur J Immunol 2002, 32:3358-3365.
113. Racioppi L., Means A.R. Calcium/calmodulin-dependent kinase IV in immune and inflammatory responses: novel routes for an ancient traveller. Trends Immunol 2008, 29:600-607.
114. Rajalingam K., Schreck R., Rapp U.R., Albert S.S. Ras oncogenes and their downstream targets. Biochem Biophys Acta 2007, 1773:1177-1196.
115. Ravandi F., Estrov Z. Eradication of leukemia stem cells as a new goal of therapy in leukemia. Clin Cancer Res 2006, 12:340-344.
116. Roberts A.B., Tian F., DaCosta Byfield S., Stuelten C., Ooshima A., Saika S., et al. Smad3 is key to TGF-β-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine Growth Factor Rev 2006, 17:19-27.
117. Rodriguez-Mora O.G., LaHair M.M., McCubrey J.A., Franklin R.A. CaM-KI and CaM-KK participate in the control of cell cycle progression in MCF-7 human breast cancer cells. Cancer Res 2005, 65:5408-5416.
118. Rodriguez-Mora O., LaHair M.M., Howe C.J., McCubrey J.A., Franklin R.A. Calcium/calmodulin-dependent protein kinases as potential targets in cancer therapy. Expert Opin Ther Targets 2005, 9:791-808.
119. Rodriguez-Mora O.G., Lahair M.M., Evans M.J., Kovacs C.J., Allison R.R., Sibata C.H., et al. Inhibition of the CaM-kinases augments cell death in response to oxygen radicals and oxygen radical inducing cancer therapies in MCF-7 human breast cancer cells. Cancer Biol Ther 2006, 5:1022-1030.
120. Rokhlin O.W., Taghiyev A.F., Bayer K.U., Bumcrot D., Koteliansk V.E., Glover R.A., et al. Calcium/calmodulin-dependent kinase II plays an important role in prostate cancer cell survival. Cancer Biol Ther 2007, 6:5.
121. Ross D.D. Novel mechanisms of drug resistance in leukemia. Leukemia 2000, 14:467-473.
122. Ross D.D. Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome. Best Pract Res Clin Haematol 2004, 17:641-651.
123. 2+/calmodulin kinase IV activity in the nucleus accumbens modulates emotional behaviour in mice. BMC Neurosci 2007, 8:105.
124. Shaul Y.D., Seger R. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochem Biophys Acta 2007, 1773:1213-1227.
125. Shaw R.J., Bordeesy N., Manning B., Lopez L., Kosmatka M., DePinto R.A. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004, 6:91-94.
126. Soderling T.R. The Ca-calmodulin-dependent protein kinase cascade. Trends Biochem Sci 1999, 24:232-236.
127. Staal S.P. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 1987, 84:5034-5037.
128. Staal S.P., Hartley J.W. Thymic lymphoma induction by the AKT8 murine retrovirus. J Exp Med 1988, 167:1259-1264.
129. Steelman L.S., Abrams S.L., Whelan J., Bertrand F.E., Ludwig D.E., Basecke J., et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and JAK/STAT pathways to leukemia. Leukemia 2008, 22:686-687.
130. Steelman L.S., Navolanic P.N., Sokolosky M., Taylor J.R., Lehmann B.D., Chappell W.H., et al. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity of mTOR inhibitors. Oncogene 2008, 27:4086-4095.
131. Steelman L.S., Stadelman K.M., Chappell W.H., Horn S., Basecke J., Cervello M., et al. Akt as a therapeutic target in cancer. Expert Opin Ther Targets 2008, 12:1139-1165.
132. 2+/calmodulin-dependent protein kinase II by protein phosphatases 1 and 2A. J Neurochem 1997, 68:2119-2128.
133. Surmacz E., Bartucci M. Role of estrogen receptor alpha in modulating IGF-I receptor signaling and function in breast cancer. J Exp Clin Cancer Res 2004, 23:385-394.
134. Suzuki K., Takahashi K. Reduced expression of the regulatory A subunit of serine/threonine protein phosphatase 2A in human breast cancer MCF-7 cells. Int J Oncol 2003, 23:1263-1268.
135. Takahashi K. The linkage between beta1 integrin and the actin cytoskeleton is differentially regulated by tyrosine and serine/threonine phosphorylation of beta1 integrin in normal and cancerous human breast cells. BMC Cell Biol 2001, 2:23.
136. Takeda H., Kitaoka Y., Hayashi Y., Kumai T., Munemasa Y., Fujino H., et al. Calcium/calmodulin-dependent protein kinase II regulates the phosphorylation of CREB in NMDA-induced retinal neurotoxicity. Brain Res 2007, 1184:306-315.
137. Tamburini J., Elie C., Bardet V., Chapuis N., Park S., Broet P., et al. Constitutive phosphoinositide-3kinase/AKT activation represents a favourable prognostic factor in de novo AML patients. Blood 2007, 110:1025-1028.
138. Tamura N., Tai Y., Sugimoto K., Kobayashi R., Konishi R., Nishioka M., et al. Enhanced expression and activation of Ca(2+)/calmodulin-dependent protein kinase IV in hepatocellular carcinoma. Cancer 2000, 89:1910-1916.
139. Tannapfel A., Sommerer F., Benicke M., Katalinic A., Uhlmann D., Witzigmann H., et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003, 52:706-712.
140. Tazzari P.L., Cappellini A., Ricci F., Evangelisti C., Papa V., Grafone T., et al. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 2007, 21:427-438.
141. Thomas R.S., Tymms M.J., McKinlay L.H., Shannon M.F., Seth A., Kola I. ETS1, NFκB and AP1 synergistically transactivate the human GM-CSF promoter. Oncogene 1997, 14:2845-2855.
142. Toker A., Cantley L.C. Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 1997, 387:673-676.
143. 2+/calmodulin-dependent protein kinase IV. Identification of a brain CaM-kinase IV kinase. J Biol Chem 1994, 269:28640-28647.
144. 2+/calmodulin-dependent protein kinases. J Biol Chem 2005, 280:35108-35118.
145. Tokunaga C., Yoshino K., Yonezawa K. mTOR integrates amino acid- and energy-sensing pathways. Biochem Biophys Res Commun 2004, 313:443-446.
146. Tombes R.M., Krystal G.W. Identification of novel human tumor cell-specific CaMK-II variants. Biochim Biophys Acta 1997, 1355:281-292.
147. Towatari M., Ciro M., Ottolenghi S., Tsuzuki S., Enver T. Involvement of the mitogen-activated protein kinase in the cytokine regulated phosphorylation of transcription factor GATA-1. Hematol J 2004, 5:262-272.
148. Tresini M., Lorenzini A., Frisoni L., Allen R.G., Cristofalo V.J. Lack of Elk-1 phosphorylation and dysregulation of the extracellular regulated kinase signaling pathway in senescent human fibroblast. Exp Cell Res 2001, 269:287-300.
149. Troppmair J., Rapp U.R. Raf and the road to cell survival: a tale of bad spells, ring bearers and detours. Biochem Pharmacol 2003, 66:1341-1345.
150. Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:855-867.
151. Wang C.Y., Bassuk A.G., Boise L.H., Thompson C.B., Bravo R., Leiden J.M. Activation of the granulocyte-macrophage colony-stimulating factor promoter in T cells requires cooperative binding of Elf-1 and AP-1 transcription factors. Mol Cell Biol 1994, 14:1153-1159.
152. Wang J., Wan W., Sun R., Liu Y., Sun X., Ma D., et al. Reduction of Akt2 expression inhibits chemotaxis signal transduction in human breast cancer cells. Cell Signal 2008, 15:15.
153. Webb C.P., Van Aelst L., Wigler M.H., Woude G.F. Signaling pathways in Ras-mediated tumorigenicity and metastasis. Proc Natl Acad Sci USA 1998, 95:8773-8778.
154. Weinstein-Oppenheimer CR, Henriquez-Roldan CF, Davis JM, Navolanic PM, Saleh OA, Steelman LS, et al. Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin. Clin Cancer Res 2001;7:2898-907.
155. Wendel H.G., De Stanchina E., Fridman J.S., Malina A., Ray S., Kogan S., et al. Survival signalling by Akt and elF4E in oncogenesis and cancer therapy. Nature 2004, 428:332-337.
156. Weng L.P., Brown J.L., Baker K.M., Ostrowski M.C., Eng C. PTEN blocks insulin-mediated ETS-2 phosphorylation through MAP kinase, independently of the phosphoinositide 3-kinase pathway. Hum Mol Genet 2002, 11:1687-1696.
157. Westphal R.S., Anderson K.A., Means A.R., Wadzinski B.E. A signaling complex of Ca2+-calmodulin-dependent protein kinase IV and protein phosphatase 2A. Science 1998, 280:1258-1261.
158. Whitfield J.F. Calcium signals and cancer. Crit Rev Oncogene 1992, 3:55-90.
159. Woodward J.K., Holen I., Coleman R.E., Buttle D.J. The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer. Bone 2007, 41:912-927.
160. Xie S., Price J.E., Luca M., Jean D., Ronai Z., Bar-Eli M. Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma cells. Oncogene 1997, 15:2069-2075.
161. Xing J., Ginty D.D., Greenberg M.E. Coupling of the Ras-MAPK pathway to gene activation by Rsk2, a growth factor regulated CREB kinase. Science 1996, 273:959-963.
162. Xu S., Robbins D., Frost J., Dang A., Lange-Carter C., Cobb M.H. MEKK1 phosphorylates MEK1 and MEK2 but does not cause activation of mitogen-activated protein kinase. Proc Natl Acad Sci USA 1995, 92:6808-6812.
163. Xu Q., Simpson S.E., Scialla T.J., Bagg A., Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003, 102:972-980.
164. Xu Q., Thompson J.E., Carroll M. mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood 2005, 106:4261-4268.
165. Yano S., Tokumitsu H., Soderling T.R. Calcium promotes cell survival through CaM-K kinase activation of the protein-kinase-B pathway. Nature 1998, 396:584-587.
166. Ye L., Gho W.M., Chan F.L., Chen S., Leung L.K. Dietary administration of the licorice flavonoid isoliquiritigenin deters the growth of MCF-7 cells overexpressing aromatase. Int J Cancer 2009, 124:1028-1036.
167. Yeung R.S., Xiao G., Jin F., Lee W., Testa J.R., Knudson A.G. Predisposition to renal carcinoma in the eker rat is determined by germline mutation of the tuberous sclerosis 2 (TSC2). Proc Natl Acad Sci USA 1994, 91:11413-11416.
168. Yilmaz O.H., Valdez R., Theisen B.K., Guo W., Ferguson D.O., Wu H., et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006, 441:475-482.
169. Yuan K., Chung L.W., Siegal G.P., Zayzafoon M. α-CaMKII controls the growth of human osteosarcoma by regulating cell cycle progression. Lab Invest 2007, 87:938-950.
170. Zhang J., Grindley J.C., Yin T., Jayasinghe S., He X.C., Ross J.T., et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 2006, 441:518-522.